
Commentary|Articles|June 24, 2026
ADA 2026: Diabetes Technology Innovations Expand Beyond Traditional CGM Use
Fact checked by: Gillian McGovern, Editor, Ron Panarotti
As these tools continue to move into mainstream diabetes management, it is increasingly important that pharmacists have proficiency.
Advertisement
Advertisement
The technology presentations at the 86th American Diabetes Association (ADA) Scientific Sessions highlighted a major shift in diabetes care. Continuous glucose monitoring (CGM) is moving beyond intensive insulin management and becoming a broader therapeutic tool for people with type 2 diabetes (T2D), while automated insulin delivery systems continue to expand and emerging ketone monitoring technologies promise to improve safety and reduce the risk of diabetic ketoacidosis (DKA).
Related to this article

At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.

Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.

A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.

Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, while sulfonylureas signaled faster decline without it.

Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.

HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.

A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Advertisement
Advertisement

